Albireo Pharma logo
Albireo Pharma ALBO
report update icon

Quarterly report 2022-Q3
added 05-23-2026

Albireo Pharma Total Assets | ALBO

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Albireo Pharma

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004
302 M 286 M 165 M 185 M 73.2 M 49.7 M 6.97 M 25.4 M 41.2 M 41.1 M 41.5 M 32.6 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
302 M 6.97 M 104 M

Quarterly Total Assets Albireo Pharma

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- 321 M 229 M 261 M 302 M 296 M 219 M 250 M 286 M 311 M 184 M 182 M 165 M 171 M 182 M 173 M 185 M 194 M 204 M 213 M 73.2 M 77.1 M 82.7 M 40.3 M 49.7 M 31.4 M 34.2 M 37.9 M 6.97 M 45.1 M 18.8 M 21 M 21 M 25.7 M 30.3 M 37 M 37 M 44.4 M 30.3 M 37.3 M 37.3 M 46.9 M 34 M 38.1 M 38.1 M 45.1 M 41.5 M 41.5 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
321 M 6.97 M 116 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
uniQure N.V. uniQure N.V.
QURE
825 M $ 19.32 -4.5 % $ 1.11 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
1.53 B $ 16.46 -4.41 % $ 1.62 B usaUSA
Rafael Holdings Rafael Holdings
RFL
83.1 M $ 0.94 5.89 % $ 48.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
453 M $ 7.16 -0.35 % $ 369 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
514 M $ 40.05 -2.78 % $ 720 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
12.3 M - -6.63 % $ 13.9 M usaUSA
I-Mab I-Mab
IMAB
2.61 B - - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
104 M $ 1.27 -8.27 % $ 49.8 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
25.6 B $ 514.68 -1.15 % $ 132 B usaUSA
Genfit SA Genfit SA
GNFT
151 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
78.3 M $ 13.67 -8.01 % $ 1.49 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
803 M - - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
99.6 M - 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
1.06 B - - $ 4.9 B britainBritain
Rezolute Rezolute
RZLT
113 M $ 3.92 -6.69 % $ 407 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
18.2 M - -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
11.3 M $ 0.63 -7.05 % $ 67.2 M britainBritain
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
97.2 M - -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
40.5 M - -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
19.7 M - - $ 12.5 M belgiumBelgium
Seer Seer
SEER
296 M $ 1.34 -3.25 % $ 74.5 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
1.66 B - - $ 3.37 B chinaChina
Summit Therapeutics Summit Therapeutics
SMMT
751 M $ 9.94 -6.01 % $ 7.43 B britainBritain
Shattuck Labs Shattuck Labs
STTK
91 M $ 4.49 -1.43 % $ 312 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
86 M $ 19.81 0.08 % $ 2.81 B britainBritain
Soligenix Soligenix
SNGX
9.24 M $ 0.22 -8.25 % $ 1.14 M usaUSA
Sanofi Sanofi
SNY
127 B $ 46.51 0.97 % $ 56.8 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
53 M $ 38.02 -6.11 % $ 29.1 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
68.9 M $ 0.74 -10.95 % $ 41.5 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
3.35 B $ 13.34 -5.86 % $ 1.34 B usaUSA
Savara Savara
SVRA
253 M $ 4.28 -17.95 % $ 952 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
87.8 M - -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
423 M - - $ 2.91 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
174 M $ 8.6 -1.38 % $ 73.1 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
562 M $ 72.94 -6.09 % $ 3.05 B usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
1.45 B $ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
1.06 B $ 63.39 -2.3 % $ 9.15 B usaUSA
Aphria Inc. Aphria Inc.
APHA
2.5 B - -0.45 % $ 4.87 B canadaCanada
Viridian Therapeutics Viridian Therapeutics
VRDN
899 M $ 29.91 -4.87 % $ 3.05 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
193 M $ 13.35 -2.73 % $ 1.8 B usaUSA
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
44.9 M - -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
176 M - -6.00 % $ 238 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
89.9 M $ 16.0 -2.2 % $ 64.2 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
120 M - - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
21.3 M - 0.38 % $ 12.9 M israelIsrael
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
633 M $ 36.89 -1.78 % $ 2.92 B canadaCanada